<DOC>
	<DOCNO>NCT02426229</DOCNO>
	<brief_summary>This study evaluate dabigatran etexilate safe use patient Scleroderma Interstitial Lung Disease . All patient receive 75mg dabigatran etexilate twice day 6 month .</brief_summary>
	<brief_title>Safety &amp; Suitability Dabigatran Inhibit Thrombin Scleroderma</brief_title>
	<detailed_description>Skin pulmonary fibrosis result substantial morbidity scleroderma ( SSc ) . Furthermore , interstitial lung disease ( ILD ) culminate pulmonary fibrosis major cause death among scleroderma patient . Studies implicate coagulation system , notably serine protease thrombin , pathogenesis SSc-ILD . Thrombin transform normal lung fibroblast scleroderma fibroblast phenotype . Dabigatran etexilate selective thrombin inhibitor FDA-approved prevention thromboembolic complication patient atrial fibrillation . Dabigatran etexilate need study potential anti-fibrotic agent treatment SSc-ILD . This study design see dabigatran etexilate safe use patient scleroderma . If , long term goal study determine whether fundamental result translate potential clinical intervention SSc-ILD test future randomize control trial .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Age ≥ 18 ≤ 70 year All patient must fulfill ACR/EULAR criterion SSc . Patients may limit ( cutaneous thicken distal , proximal elbow knee , without facial involvement ) diffuse ( cutaneous thicken proximal elbow knee , often involve chest abdomen ) cutaneous SSc , systemic sclerosis sine scleroderma SSc le 7 year , onset define date first nonRaynaud phenomenon manifestation . All patient must interstitial lung disease define ground glass HRCT &gt; 20 % involvement HRCT pulmonary fibrosis and/or FVC &lt; 70 % predicted Inability sign consent Currently enrol another clinical trial FVC &lt; 40 % predict and/or DLCO ( correct hemoglobin ) &lt; 30 % predict ( suggest severe probably irreparable disease ) Other serious concomitant medical illness ( e.g. , cancer ) limit life expectancy &lt; 1 year time enrollment FEV1/FVC ratio &lt; 65 % ( suggest obstructive disease ) Clinically significant pulmonary hypertension require treatment , base clinician 's judgment . Smoking cigar , pipe cigarette within 3 month prior enrollment Clinically significant abnormality chest xray interstitial lung disease ( e.g. , lung mass , evidence active pulmonary infection , emphysema ) Use prednisone ( equivalent ) dose &gt; 10 mg daily within 3 month prior enrollment Use colchicine , Dpenicillamine , cyclophosphamide , mycophenolate mofetil , azathioprine , endothelin receptor antagonist , phosphodiesterase type5 inhibitor , prostanoids , tyrosine kinase inhibitor , sirolimus , rituximab , perfinidone `` disease modifying medication '' within 3 month prior enrollment Pregnancy lack use birth control method woman childbearing age lactate Liver disease increase baseline liver enzyme level ( ALT &gt; 3 x upper limit normal ) Use CYP450 inhibitors/inducers Hemoglobin &lt; 10g/L If child bear potential , unwillingness employ reliable mean contraception ( condom , abstinence , IUD , tubal ligation , vasectomy ) Active infection Creatinine clearance &lt; 30 ml/min Post transplantation Active medical psychiatric condition investigator may consider would interfere subject 's treatment , assessment , compliance protocol Anticoagulationrelated exclusion include : 1 . Current anticoagulation therapy warfarin 2 . Increased risk bleeding ( e.g. , uncorrectable inherit acquire bleed disorder ) 3 . Platelet count &lt; 100,000/cmm hematocrit &lt; 30 % &gt; 55 % 4 . History severe gastrointestinal bleeding within 6 month screen 5 . Known gastric antral vascular ectasia ( GAVE ) gastric/intestinal arterialvenous malformation ( AVMs ) 6 . History CVA within 6 month screen 7 . History risk fall judged PI 8 . Surgery major trauma within past 30 day 9 . Any condition , determination PI , likely require anticoagulation therapy study 10 . Clopidogrel , prasugrel antiplatelet therapy within 6 month screen 11 . Aspirin therapy &gt; 325 mg daily 12 . Therapy thrombin inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SSc</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>cutaneous systemic sclerosis</keyword>
</DOC>